Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership
Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership
08/26/20, 12:18 PM
Location
london
Money raised
$4 million
Round Type
series a
Hikma Pharmaceuticals PLC (Hikma) announces that its venture capital arm, Hikma Ventures has participated in a CAD4.0 million Series A round of financing for SeamlessMD. The round was led by MEDTEQ, bringing the company's total funding to CAD7.4 million. Anges Québec, AIoT Health, and health IT entrepreneur Sanjay Malaviya also participated in the oversubscribed round.
Company Info
Location
london, ontario, canada
Additional Info
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
SOURCE Hikma Pharmaceuticals USA Inc.